New Record High for German Chemical Industry's R&D Budget

  • Author: ChemistryViews.org
  • Published: 25 August 2018
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
  • Source / Publisher: Verband der Chemischen Industrie e.V. (VCI), Germany
thumbnail image: New Record High for German Chemical Industry's R&D Budget

In 2018, the R&D spending of the German chemical-pharmaceutical industry will reach the 11-billion-euro mark for the first time, according to the forecast of Thomas Wessel, chairman of the VCI committee for research, science, and education. In 2017, the R&D budget went up to the then-record total of 10.8 billion euros. That was an increase of 3 % over the previous year 2016. Thus, there was a rise in the industry’s funds for research and development for seven consecutive years.


In a comparison of industries, the chemical-pharmaceutical industry has the strongest innovation orientation. 63 % of all chemical and pharmaceutical companies are engaged in research. This puts the sector above the average of German industry as a whole (28 %). The chemical industry dedicates over 5 % of sales to research annually. The R&D intensity is only higher in vehicle construction and in the electrical industry.

Even though there are many strengths in R&D, Wessel is concerned about the international innovation pressure: Countries like the USA, China, or other Asian nations make huge investments in research and provide a favorable framework for innovation. Thus, they are gaining competitive advantages. Wessel calls upon the German government "to take a courageous route for modernization, as this is the only option for Germany to hold its own in the global race for innovation—competing with research superpowers such as the USA, China, or South Korea."

Wessel sees fiscal incentives for R&D as a central instrument for improving the quality of Germany as an innovation location. According to the chairman, such incentives are crucial for research investments by the overall economy to rise to 3.5 %. In this respect, Germany currently is ranked only seventh internationally. Almost all OECD countries use the mentioned incentives to drive forward research.

Wessel calls for more openness for new technologies so that innovations can really thrive in Germany.  In this context, Wessel regrets the recent judgment of the European Court of Justice on genome editing which, in his opinion, is not based on existing scientific facts but blocks the potential of CRISPR/Cas and comparable methods.


 

Article Views: 548

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH